In our pilot study, we measured peripheral blood plasma concentrations of sCD105 using comercially available enzyme-linked immunosorbent assay in 75 patients with lymphoid malignancies and 13 healthy donors. We found a statistically significant increase in sCD105 concentrations in patients with B-cell chronic lymphocytic leukemia compared to the control group (p=0.0296).
Suprisingly, patients with multiple myeloma had significantly lower concentrations of sCD105 in comparison to controls We didn’t find significant differences between sCD105 concentrations in patients with follicular lymphoma or diffuse large B-cell lymphoma and the control group.